Get the Stockscreener App
27.49
3.97%
1.05
Bridgebio Pharma Inc Stock (BBIO) Latest News
HC Wainwright Analysts Increase Earnings Estimates for BBIO - MarketBeat
What is Leerink Partnrs' Forecast for BBIO FY2024 Earnings? - MarketBeat
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug - MSN
BridgeBio Pharma (FRA:2CL) Total Liabilities : €1,696.9 Mil (As of Sep. 2024) - GuruFocus.com
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby - Marketscreener.com
BridgeBio's Attruby (Acoramidis) Approval Could Pave Way for Long-Term Profitability - Morningstar
Leerink Partnrs Expects Weaker Earnings for BridgeBio Pharma - MarketBeat
BridgeBio price target raised to $45 from $42 at BofA - Yahoo Finance
Eagle Asset Management Inc. Lowers Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Algert Global LLC Has $3.47 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Massachusetts Financial Services Co. MA Grows Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds - MSN
BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer - MSN
FDA approves BridgeBio’s Attruby for ATTR-CM treatment - Indian Pharma Post
BridgeBio Pharma Receive FDA Nod for Attruby - Diagnostic and Interventional Cardiology
BridgeBio’s Attruby Could Benefit From ‘Best-Case’ Label, Lower Price - Citeline
BridgeBio Soars After Drug Gets Nod in Rare Heart Condition - MSN
Health Care Up Amid Cyclical Bias -- Health Care Roundup - Marketscreener.com
Bridgebio, with FDA approval, faces Pfizer in ATTR - BioWorld Online
Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race - FirstWord Pharma
BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug - Investor's Business Daily
Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY™ (acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis - Yahoo Finance
Gold Down Over 3%; Rigetti Computing Shares Spike Higher - Benzinga
FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug - MedCity News
BridgeBio's SWOT analysis: genetic disease fighter's stock faces pivotal moment - Investing.com
BridgeBio stock retains Overweight; Piper Sandler highlights competitive pricing for Attruby - Investing.com
US FDA approves BridgeBio's drug for rare heart condition (Nov 22) - Reuters.com
BridgeBio stock remains Market Perform; BMO cites key milestone in regulatory progress - Investing.com
BridgeBio shares surge 25% on FDA approval of Attruby - Investing.com
FDA approves Palo Alto biotech's heart disease drug - The Business Journals
BridgeBio shares maintain buy rating on positive Attruby launch outlook - Investing.com
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up Following Analyst Upgrade - MarketBeat
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday - Inkl
BridgeBio Soars After Drug Gets Nod in Serious Heart Condition - MSN
BridgeBio price target raised to $48 from $45 at Scotiabank - TipRanks
BridgeBio shares retain Buy rating as H.C. Wainwright highlights Attruby FDA approval - Investing.com
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug - Yahoo! Voices
BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby - MarketWatch
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America - MarketBeat
HC Wainwright Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy - FiercePharma
FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM - PMLiVE
BridgeBio gets FDA nod for Attruby to treat ATTR-CM patients - World Pharmaceutical Frontiers
BridgeBio Pharma Obtains FDA Approval of Attruby - Marketscreener.com
BBIO (BridgeBio Pharma) Long-Term Capital Lease Obligation : $5.8 Mil (As of Sep. 2024) - GuruFocus.com
BridgeBio’s Attruby wins FDA approval - The Pharma Letter
BridgeBio poised to challenge Pfizer after Attruby approval - pharmaphorum
BridgeBio: Next Chapter Begins After Attruby Approval - Seeking Alpha
B. Metzler seel. Sohn & Co. Holding AG Buys Shares of 36,603 BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Jennison Associates LLC Buys New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby - Seeking Alpha
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer - BioSpace
BridgeBio clinches key approval for heart disease drug - FirstWord Pharma
FDA Approves Acoramidis (Attruby) for ATTR-CM - MD Magazine
BridgeBio heart drug approved by FDA, setting up battle with Pfizer - BioPharma Dive
BridgeBio wins FDA approval for heart disease drug - STAT
BridgeBio's Attruby Wins FDA Approval: 42% Reduction in ATTR-CM Mortality & Hospitalizations | BBIO Stock News - StockTitan
Attruby™ (acoramidis), a Near Complete TTR Stabilizer - GlobeNewswire
Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):